亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

医学 甘精胰岛素 2型糖尿病 内科学 磺酰脲 二甲双胍 临床终点 随机对照试验 体质指数 糖尿病 低血糖 内分泌学 胰岛素 不利影响
作者
Stefano Del Prato,Steven E. Kahn,Imre J. Pavo,Govinda J. Weerakkody,Zhengyu Yang,John Doupis,Diego Aizenberg,Alan G Wynne,Jeffrey S. Riesmeyer,Robert J. Heine,Russell J. Wiese,Andrew Ahmann,Samir Arora,Eric M. Ball,Rafael B Calderon,David Butuk,Leila Chaychi,Michael C. Chen,Brian M. Curtis,Ronald H. Chochinov
出处
期刊:The Lancet [Elsevier BV]
卷期号:398 (10313): 1811-1824 被引量:820
标识
DOI:10.1016/s0140-6736(21)02188-7
摘要

We aimed to assess efficacy and safety, with a special focus on cardiovascular safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk inadequately controlled on oral glucose-lowering medications.This open-label, parallel-group, phase 3 study was done in 187 sites in 14 countries on five continents. Eligible participants, aged 18 years or older, had type 2 diabetes treated with any combination of metformin, sulfonylurea, or sodium-glucose co-transporter-2 inhibitor, a baseline glycated haemoglobin (HbA1c) of 7·5-10·5% (58-91 mmol/mol), body-mass index of 25 kg/m2 or greater, and established cardiovascular disease or a high risk of cardiovascular events. Participants were randomly assigned (1:1:1:3) via an interactive web-response system to subcutaneous injection of either once-per-week tirzepatide (5 mg, 10 mg, or 15 mg) or glargine (100 U/mL), titrated to reach fasting blood glucose of less than 100 mg/dL. The primary endpoint was non-inferiority (0·3% non-inferiority boundary) of tirzepatide 10 mg or 15 mg, or both, versus glargine in HbA1c change from baseline to 52 weeks. All participants were treated for at least 52 weeks, with treatment continued for a maximum of 104 weeks or until study completion to collect and adjudicate major adverse cardiovascular events (MACE). Safety measures were assessed over the full study period. This study was registered with ClinicalTrials.gov, NCT03730662.Patients were recruited between Nov 20, 2018, and Dec 30, 2019. 3045 participants were screened, with 2002 participants randomly assigned to tirzepatide or glargine. 1995 received at least one dose of tirzepatide 5 mg (n=329, 17%), 10 mg (n=328, 16%), or 15 mg (n=338, 17%), or glargine (n=1000, 50%), and were included in the modified intention-to-treat population. At 52 weeks, mean HbA1c changes with tirzepatide were -2·43% (SD 0·05) with 10 mg and -2·58% (0·05) with 15 mg, versus -1·44% (0·03) with glargine. The estimated treatment difference versus glargine was -0·99% (multiplicity adjusted 97·5% CI -1·13 to -0·86) for tirzepatide 10 mg and -1·14% (-1·28 to -1·00) for 15 mg, and the non-inferiority margin of 0·3% was met for both doses. Nausea (12-23%), diarrhoea (13-22%), decreased appetite (9-11%), and vomiting (5-9%) were more frequent with tirzepatide than glargine (nausea 2%, diarrhoea 4%, decreased appetite <1%, and vomiting 2%, respectively); most cases were mild to moderate and occurred during the dose-escalation phase. The percentage of participants with hypoglycaemia (glucose <54 mg/dL or severe) was lower with tirzepatide (6-9%) versus glargine (19%), particularly in participants not on sulfonylureas (tirzepatide 1-3% vs glargine 16%). Adjudicated MACE-4 events (cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina) occurred in 109 participants and were not increased on tirzepatide compared with glargine (hazard ratio 0·74, 95% CI 0·51-1·08). 60 deaths (n=25 [3%] tirzepatide; n=35 [4%] glargine) occurred during the study.In people with type 2 diabetes and elevated cardiovascular risk, tirzepatide, compared with glargine, demonstrated greater and clinically meaningful HbA1c reduction with a lower incidence of hypoglycaemia at week 52. Tirzepatide treatment was not associated with excess cardiovascular risk.Eli Lilly and Company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
jf完成签到 ,获得积分10
3秒前
科研通AI6.3的应助被灵剑山采纳,获得10
3秒前
缥缈的鸡翅完成签到,获得积分10
6秒前
leafy189完成签到,获得积分10
8秒前
ASZI完成签到 ,获得积分10
9秒前
10秒前
愉快的惋庭完成签到,获得积分10
13秒前
13秒前
KKIII完成签到,获得积分10
15秒前
ldxghh发布了新的文献求助10
15秒前
16秒前
梦梦的应助被盖世小么得采纳,获得10
16秒前
完美世界的应助被dd采纳,获得10
21秒前
23秒前
真实的曼柔完成签到 ,获得积分10
24秒前
26秒前
27秒前
31秒前
31秒前
悦兮的应助被科研通管家采纳,获得10
31秒前
花痴的向卉完成签到,获得积分10
32秒前
朴素半烟完成签到 ,获得积分10
32秒前
打打的应助被科研通管家采纳,获得10
32秒前
32秒前
KKIII发布了新的文献求助10
35秒前
2589完成签到,获得积分10
35秒前
淡然的冰淇淋完成签到 ,获得积分10
43秒前
坦率的邑完成签到 ,获得积分10
51秒前
55秒前
冷酷的祥完成签到,获得积分10
55秒前
睡觉大王__完成签到,获得积分10
57秒前
科研小白发布了新的文献求助10
58秒前
obedVL完成签到,获得积分10
59秒前
风趣含双发布了新的文献求助10
1分钟前
背后寒烟完成签到 ,获得积分10
1分钟前
Yh完成签到,获得积分10
1分钟前
从容棉花糖完成签到,获得积分10
1分钟前
cloud完成签到 ,获得积分10
1分钟前
Yh发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565447
关于积分的说明 21780029
捐赠科研通 7764817
什么是DOI,文献DOI怎么找? 3431496
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476571